iOR Holdings, Inc. secured a Series D Preferred round to drive growth while preparing for CMS reimbursement approval, focusing on the transition of ophthalmic surgeries to office-based settings.

Information on the Target

iOR Holdings, Inc., also known as iOR Partners, has successfully concluded a Series D Preferred round to support its growth in the ophthalmology sector, particularly as it seeks reimbursement approval from the Centers for Medicare & Medicaid Services (CMS). Headquartered in Kansas City, Missouri, iOR Partners offers an innovative business model that facilitates the transition of ophthalmic lens replacement surgery from traditional hospital and ambulatory surgery center (ASC) settings directly to the surgeon's office. This model allows for a more personalized and premium surgical experience for patients.

Currently, iOR Partners has more than 100 iOR Suites operational or in development, having led to over 100,000 successful surgical outcomes. The company collaborates with ophthalmic surgeons for the turnkey development of office-based surgical suites, providing essential guidance on feasibility, profitability, space planning, and timelines while ensuring compliance with operational standards.

Industry Overview in the Target’s Country

The ophthalmology sector in the United States is experiencing significant growth, driven by the rising demand for cataract and refractive lens exchange surgeries. Annually, more than four million